Skip to main content
Erschienen in: The European Journal of Health Economics 3/2006

01.09.2006 | Original Papers

The costs of schizophrenia in Spain

verfasst von: Juan Oliva-Moreno, Julio López-Bastida, Rubén Osuna-Guerrero, Angel Luis Montejo-González, Beatriz Duque-González

Erschienen in: The European Journal of Health Economics | Ausgabe 3/2006

Einloggen, um Zugang zu erhalten

Abstract

This study estimated the economic impact of schizophrenia-related direct costs (medical and nonmedical costs) in Spain. Direct medical costs (hospitalizations, outpatient consultations, drug costs) and direct nonmedical costs (costs of informal care) were estimated based on prevalence costs for 2002. The total costs of schizophrenia were estimated at €1,970.8 million; direct medical costs accounted for 53% and informal care costs 47%. Despite having implemented a conservative approach, the health care costs associated with schizophrenia account for 2.7% of total public health care expenditure in Spain. The sum of medical and nonmedical costs give us a better definition of the magnitude of the problem in Spain as well as contributing to helping make the debate on this issue more transparent.
Literatur
1.
Zurück zum Zitat Anonymous (1993) Report on choices in health care. Ministry of Health, Welfare and Cultural Affairs: The Netherlands Anonymous (1993) Report on choices in health care. Ministry of Health, Welfare and Cultural Affairs: The Netherlands
2.
Zurück zum Zitat Anonymous (2001) Estadísticas de establecimientos sanitarios con régimen de internado. Ministry of Health Care and Consumer Affairs: Madrid Anonymous (2001) Estadísticas de establecimientos sanitarios con régimen de internado. Ministry of Health Care and Consumer Affairs: Madrid
3.
Zurück zum Zitat Anonymous (2002) Información terapéutica del sistema nacional de salud, vol 26, no 2. General Directorate of Pharmacy, Ministry of Health Care and Consumer Affairs: Madrid Anonymous (2002) Información terapéutica del sistema nacional de salud, vol 26, no 2. General Directorate of Pharmacy, Ministry of Health Care and Consumer Affairs: Madrid
4.
Zurück zum Zitat Anonymous (2002) Información terapéutica del sistema nacional de salud. vol 28, no 2–. General Directorate of Pharmacy, Ministry of Health Care and Consumer Affairs: Madrid Anonymous (2002) Información terapéutica del sistema nacional de salud. vol 28, no 2–. General Directorate of Pharmacy, Ministry of Health Care and Consumer Affairs: Madrid
5.
Zurück zum Zitat Anonymous (2003) Estudio Depresión Monitor. TNS healthcare Anonymous (2003) Estudio Depresión Monitor. TNS healthcare
6.
Zurück zum Zitat Baca E, Roca M, Varela C, on behalf of the ACE Group (2004) Prevalence of comorbidities in ambulatory schizophrenic patients treated with antipsychotics. Poster presented at the ECNP, Stockholm Baca E, Roca M, Varela C, on behalf of the ACE Group (2004) Prevalence of comorbidities in ambulatory schizophrenic patients treated with antipsychotics. Poster presented at the ECNP, Stockholm
7.
Zurück zum Zitat Baca E, Roca M, Varela C, on behalf of the ACE Group (2004) Treatment profile of schizophrenic outpatients in Spain. Poster presented at the CINP, Paris Baca E, Roca M, Varela C, on behalf of the ACE Group (2004) Treatment profile of schizophrenic outpatients in Spain. Poster presented at the CINP, Paris
8.
Zurück zum Zitat Berg B van den, Brouwer W, Koopmanschap M (2004) Economic valuation of informal care: an overview of methods and applications. Eur J Health Econ 5: 36–45CrossRefPubMed Berg B van den, Brouwer W, Koopmanschap M (2004) Economic valuation of informal care: an overview of methods and applications. Eur J Health Econ 5: 36–45CrossRefPubMed
9.
Zurück zum Zitat Carr VJ, Neil AL, Halpin SA et al. (2003) Costs of schizophrenia and other psychoses in urban Australia: findings from the Low Prevalence (Psychotic) Disorders Study. Aust N Z J Psychiatry 37: 31–40CrossRefPubMed Carr VJ, Neil AL, Halpin SA et al. (2003) Costs of schizophrenia and other psychoses in urban Australia: findings from the Low Prevalence (Psychotic) Disorders Study. Aust N Z J Psychiatry 37: 31–40CrossRefPubMed
10.
Zurück zum Zitat Clark RE, Xie H, Adarhi-Meija AM, Sergupta A (2001) Substitution between formal and informal care for persons with severe mental illness and substance use disorders. J Ment Health Policy Econ 4: 123–132PubMed Clark RE, Xie H, Adarhi-Meija AM, Sergupta A (2001) Substitution between formal and informal care for persons with severe mental illness and substance use disorders. J Ment Health Policy Econ 4: 123–132PubMed
11.
Zurück zum Zitat Davis LM, Drummond MF (1994) Economics and schizophrenia: the real cost. Br J Psychiatry 165: 18–21 Davis LM, Drummond MF (1994) Economics and schizophrenia: the real cost. Br J Psychiatry 165: 18–21
12.
Zurück zum Zitat Díaz Berenguer JA, López Cabañas A, Cabeza Mora A (nd) Área técnica de la gerencia de atención primaria del Áreas de salud de Gran Canarias. Canary Islands Health Service Díaz Berenguer JA, López Cabañas A, Cabeza Mora A (nd) Área técnica de la gerencia de atención primaria del Áreas de salud de Gran Canarias. Canary Islands Health Service
13.
Zurück zum Zitat Durán MA (2002) Los costes invisibles de la enfermedad. Fundación BBVA: Bilbao Durán MA (2002) Los costes invisibles de la enfermedad. Fundación BBVA: Bilbao
14.
Zurück zum Zitat Evers SMAA, Ament AJHA (1995) Costs of schizophrenia in The Netherlands. Schizophr Bull 21: 141–153PubMed Evers SMAA, Ament AJHA (1995) Costs of schizophrenia in The Netherlands. Schizophr Bull 21: 141–153PubMed
15.
Zurück zum Zitat Foldemo A, Gullberg M, Ek AC, Bogren L (2005) Quality of life and burden in parents of outpatients with schizophrenia. Soc Psychiatry Psychiatr Epidemiol 40: 133–138CrossRefPubMed Foldemo A, Gullberg M, Ek AC, Bogren L (2005) Quality of life and burden in parents of outpatients with schizophrenia. Soc Psychiatry Psychiatr Epidemiol 40: 133–138CrossRefPubMed
16.
Zurück zum Zitat Frank RG, Berndt ER, Busch AB, Lehman AF (2003) Quality-constant price indexes for the ongoing treatment of schizophrenia: an exploratory study. NBER working paper no 10022 Frank RG, Berndt ER, Busch AB, Lehman AF (2003) Quality-constant price indexes for the ongoing treatment of schizophrenia: an exploratory study. NBER working paper no 10022
17.
Zurück zum Zitat Garattini L, Barbui C, Clemente R et al., on behalf of the Study Group SCORE (2004) Direct costs of schizophrenia and related disorders in Italy community mental health services: a multicenter, prospective 1-year follow up study. Schizophr Bull 30: 295–302PubMed Garattini L, Barbui C, Clemente R et al., on behalf of the Study Group SCORE (2004) Direct costs of schizophrenia and related disorders in Italy community mental health services: a multicenter, prospective 1-year follow up study. Schizophr Bull 30: 295–302PubMed
18.
Zurück zum Zitat Gisbert R, Brosa M, Figueras M et al. (1998) El coste de la enfermedad en España: el coste de las enfermedades cardiovasculares. Merck Sharp & Dohme: Madrid Gisbert R, Brosa M, Figueras M et al. (1998) El coste de la enfermedad en España: el coste de las enfermedades cardiovasculares. Merck Sharp & Dohme: Madrid
19.
Zurück zum Zitat Goeree R, O’Brien BJ, Goering P et al. (1999) The economic burden of schizophrenia in Canada. Can J Psychiatry 44: 464–472PubMed Goeree R, O’Brien BJ, Goering P et al. (1999) The economic burden of schizophrenia in Canada. Can J Psychiatry 44: 464–472PubMed
20.
Zurück zum Zitat Goeree R, Farahati F, Burke N et al. (2005) The economic burden of schizophrenia in Canada in 2004. Curr Med Res Opin 21: 2017–2028CrossRefPubMed Goeree R, Farahati F, Burke N et al. (2005) The economic burden of schizophrenia in Canada in 2004. Curr Med Res Opin 21: 2017–2028CrossRefPubMed
21.
Zurück zum Zitat Gold MR, Siegel JE, Russell LB, Weinstein MC (1996) Cost-effectiveness in health and medicine. Oxford University Press: New York Gold MR, Siegel JE, Russell LB, Weinstein MC (1996) Cost-effectiveness in health and medicine. Oxford University Press: New York
22.
Zurück zum Zitat Greenhalgh J, Knight C, Hind D et al. (2005) Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies. Health Technol Assess 9: 1–170 Greenhalgh J, Knight C, Hind D et al. (2005) Clinical and cost-effectiveness of electroconvulsive therapy for depressive illness, schizophrenia, catatonia and mania: systematic reviews and economic modelling studies. Health Technol Assess 9: 1–170
23.
Zurück zum Zitat Guest JF, Cookson RF (1999) Cost of schizophrenia to U.K. society. Pharmacoeconomics 15: 597–610PubMed Guest JF, Cookson RF (1999) Cost of schizophrenia to U.K. society. Pharmacoeconomics 15: 597–610PubMed
24.
Zurück zum Zitat Haro JM, Salvador-Carrulla L, Cabases J et al. (1998) Utilisation of mental health services and costs of patients with schizophrenia in three areas of Spain. Br J Psychiatry 173: 334–340PubMed Haro JM, Salvador-Carrulla L, Cabases J et al. (1998) Utilisation of mental health services and costs of patients with schizophrenia in three areas of Spain. Br J Psychiatry 173: 334–340PubMed
25.
Zurück zum Zitat Hodgson TA, Meiners MR (1982) Cost-of-illness methodology: a guide to assessment practices and procedures. Milbank Q 60: 429–491 Hodgson TA, Meiners MR (1982) Cost-of-illness methodology: a guide to assessment practices and procedures. Milbank Q 60: 429–491
26.
Zurück zum Zitat Johnstone EC, Frith CD, Leary J et al. (1991) Background, method and general description of the sample. Br J Psychiatry 159 [Suppl 13]: 43–46 Johnstone EC, Frith CD, Leary J et al. (1991) Background, method and general description of the sample. Br J Psychiatry 159 [Suppl 13]: 43–46
27.
Zurück zum Zitat Kaplan-Sadock (2004) Sinopsis de psiquiatría, 9th edn. Waverly Hispánica: Madrid Kaplan-Sadock (2004) Sinopsis de psiquiatría, 9th edn. Waverly Hispánica: Madrid
28.
Zurück zum Zitat Knapp M (1997) Costs of schizophrenia. Br J Psychiatry 171: 509–515PubMed Knapp M (1997) Costs of schizophrenia. Br J Psychiatry 171: 509–515PubMed
29.
Zurück zum Zitat Loosbrock DL, Zhao Z, Johnstone BM, Morris LS (2003) Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia. J Ment Health Policy Econ 2003 6: 67–75 Loosbrock DL, Zhao Z, Johnstone BM, Morris LS (2003) Antipsychotic medication use patterns and associated costs of care for individuals with schizophrenia. J Ment Health Policy Econ 2003 6: 67–75
30.
Zurück zum Zitat Magliano L, Fadden G, Madianos M et al. (1998) Burden on the families of patients with schizophrenia: results of the BIOMED I study. Soc Psychiatry Psychiatr Epidemiol 33: 405–412CrossRefPubMed Magliano L, Fadden G, Madianos M et al. (1998) Burden on the families of patients with schizophrenia: results of the BIOMED I study. Soc Psychiatry Psychiatr Epidemiol 33: 405–412CrossRefPubMed
31.
Zurück zum Zitat Martínez A, Nadal S, Beperet M, Mendioroz P and the Grupo Psicot (2000) Sobrecarga de los cuidados familiares de pacientes con esquizofrenia: factores determinantes. Anal Sis San Navarra 23: 101–110 Martínez A, Nadal S, Beperet M, Mendioroz P and the Grupo Psicot (2000) Sobrecarga de los cuidados familiares de pacientes con esquizofrenia: factores determinantes. Anal Sis San Navarra 23: 101–110
32.
Zurück zum Zitat Mata I, Beperet M, Madoz V and the grupo Psicost (2000) Prevalencia e incidencia de la esquizofrenia en Navarra. Anal Sis San Navarra 23 [Suppl 1]: 29–36 Mata I, Beperet M, Madoz V and the grupo Psicost (2000) Prevalencia e incidencia de la esquizofrenia en Navarra. Anal Sis San Navarra 23 [Suppl 1]: 29–36
33.
Zurück zum Zitat Max W, Rice DP, Mackenzie EJ (1990) The lifetime cost of injury. Inquiry 27: 332–343PubMed Max W, Rice DP, Mackenzie EJ (1990) The lifetime cost of injury. Inquiry 27: 332–343PubMed
34.
Zurück zum Zitat Montejo AL, Majadas S and the Grupo GEOPTE (2006) Análisis de los patrones de prescripción de antipsicóticos en Psiquiatría. Actas Esp Psiquiatr (in press) Montejo AL, Majadas S and the Grupo GEOPTE (2006) Análisis de los patrones de prescripción de antipsicóticos en Psiquiatría. Actas Esp Psiquiatr (in press)
35.
Zurück zum Zitat Oliva J, Lobo F, Molina B, Monereo S (2004) Direct health care costs of diabetic patients in Spain. Diabetes Care 27: 2616–2621PubMed Oliva J, Lobo F, Molina B, Monereo S (2004) Direct health care costs of diabetic patients in Spain. Diabetes Care 27: 2616–2621PubMed
36.
Zurück zum Zitat Oliva J, Lobo F, López-Bastida J et al. (2005) Indirect costs of cervical and breast cancer in Spain. Eur J Health Econ 6: 309–313CrossRefPubMed Oliva J, Lobo F, López-Bastida J et al. (2005) Indirect costs of cervical and breast cancer in Spain. Eur J Health Econ 6: 309–313CrossRefPubMed
37.
Zurück zum Zitat Pang F (2002) Design, analysis and presentation of multinational economic studies; the need for guidance. Pharmacoeconomics 20: 75–90CrossRefPubMed Pang F (2002) Design, analysis and presentation of multinational economic studies; the need for guidance. Pharmacoeconomics 20: 75–90CrossRefPubMed
38.
Zurück zum Zitat Rice D, Miller LS (1996) The economic burden of schizophrenia: conceptual and methodological issues and costs estimates. In: Moscarelli M, Rupp A and Sartorius N (eds) Handbook of mental health economics and health policy, vol 1. Wiley: Chichester Rice D, Miller LS (1996) The economic burden of schizophrenia: conceptual and methodological issues and costs estimates. In: Moscarelli M, Rupp A and Sartorius N (eds) Handbook of mental health economics and health policy, vol 1. Wiley: Chichester
39.
Zurück zum Zitat Robinson JC (1986) Philosophical origins of the economic valuation of life. Milbank Q 64: 133–155PubMed Robinson JC (1986) Philosophical origins of the economic valuation of life. Milbank Q 64: 133–155PubMed
40.
Zurück zum Zitat Rouillon F, Toumi M, Dansette GY et al. (1997) Some aspects of the cost of squizophrenia in France. Pharmacoeconomics 11: 578–594PubMed Rouillon F, Toumi M, Dansette GY et al. (1997) Some aspects of the cost of squizophrenia in France. Pharmacoeconomics 11: 578–594PubMed
41.
Zurück zum Zitat Salvador-Carulla L, Haro JM, Cabases J et al. (1999) Service utilization and costs of first-onset schizophrenia in two widely differing health service areas in north-east Spain. PSICOST Group. Acta Psychiatr Scand 100: 335–343PubMed Salvador-Carulla L, Haro JM, Cabases J et al. (1999) Service utilization and costs of first-onset schizophrenia in two widely differing health service areas in north-east Spain. PSICOST Group. Acta Psychiatr Scand 100: 335–343PubMed
42.
Zurück zum Zitat SEPB, SEMERGEN and SEP (2003) Uso y seguimiento del tratamiento con antidepresivos en atención primaria en España. Scientific Comunication Management: Madrid SEPB, SEMERGEN and SEP (2003) Uso y seguimiento del tratamiento con antidepresivos en atención primaria en España. Scientific Comunication Management: Madrid
43.
Zurück zum Zitat Sainsbury Centre for Mental Health (2003) The economic and social costs of mental illness. Sainsbury Centre for Mental Health: London Sainsbury Centre for Mental Health (2003) The economic and social costs of mental illness. Sainsbury Centre for Mental Health: London
44.
Zurück zum Zitat Vázquez-Barquero JL, Diez Manrique JF, Pena C et al. (1987) A community mental health survey in Cantabria: a general description of morbidity. Psychol Med 17: 227–241PubMed Vázquez-Barquero JL, Diez Manrique JF, Pena C et al. (1987) A community mental health survey in Cantabria: a general description of morbidity. Psychol Med 17: 227–241PubMed
45.
Zurück zum Zitat Vos T, Haby MM, Magnus A et al. (2005) Assessing cost-effectiveness in mental health: helping policy-makers prioritize and plan health services. Aust N Z J Psychiatry 39: 701–712CrossRefPubMed Vos T, Haby MM, Magnus A et al. (2005) Assessing cost-effectiveness in mental health: helping policy-makers prioritize and plan health services. Aust N Z J Psychiatry 39: 701–712CrossRefPubMed
46.
Zurück zum Zitat Wu EQ, Birnbaum HG, Shi L et al. (2005) The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 66: 1122–1129PubMed Wu EQ, Birnbaum HG, Shi L et al. (2005) The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry 66: 1122–1129PubMed
47.
Zurück zum Zitat Wyatt RJ, Henter I, Leary MC, Taylor E (1995) An economic evaluation of schizophrenia 1991. Soc Psychiatry Psychiatr Epidemiol 30: 196–205PubMed Wyatt RJ, Henter I, Leary MC, Taylor E (1995) An economic evaluation of schizophrenia 1991. Soc Psychiatry Psychiatr Epidemiol 30: 196–205PubMed
Metadaten
Titel
The costs of schizophrenia in Spain
verfasst von
Juan Oliva-Moreno
Julio López-Bastida
Rubén Osuna-Guerrero
Angel Luis Montejo-González
Beatriz Duque-González
Publikationsdatum
01.09.2006
Verlag
Springer-Verlag
Erschienen in
The European Journal of Health Economics / Ausgabe 3/2006
Print ISSN: 1618-7598
Elektronische ISSN: 1618-7601
DOI
https://doi.org/10.1007/s10198-006-0350-5

Weitere Artikel der Ausgabe 3/2006

The European Journal of Health Economics 3/2006 Zur Ausgabe